AG
CRVS icon

Advisor Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Advisor Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$5K Hold
1,000
– – ﹤0.01% 4645
2019
Q3 		$3K Hold
1,000
– – ﹤0.01% 4821
2019
Q2 		$4K Buy
+1,000
New +$3.92K ﹤0.01% 4741

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Advisor Group's CRVS Position: Q4 2019 in Review

Advisor Group held its Corvus Pharmaceuticals (CRVS) position steady in Q4 2019 at 1,000 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #4645.

Advisor Group first reported a position in CRVS in Q2 2019 and has held it in 3 quarters since. 37 funds tracked by Wall St. Rank hold CRVS as of Q4 2019.

  • Advisor Group held 1,000 shares of Corvus Pharmaceuticals worth $5K as of Q4 2019.
  • Advisor Group left its Corvus Pharmaceuticals share count unchanged in Q4 2019.
  • Corvus Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4645 holding.
  • Advisor Group first reported a position in Corvus Pharmaceuticals in Q2 2019 and has held it in 3 quarters since.
  • 37 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.